The present invention relates to lipolysis generally and more particularly to ultrasonic lipolysis.
The following U.S. patents are believed to represent the current state of the art: U.S. Pat. Nos. 4,986,275; 5,143,063; 5,143,073; 5,209,221; 5,301,660; 5,431,621; 5,507,790; 5,526,815; 5,884,631; 6,039,048; 6,071,239; 6,113,558; 6,206,873.
There is provided, in accordance with an embodiment, an apparatus for lysing adipose tissue, the apparatus comprising: a power source and modulator assembly configured to supply modulated electrical power; an ultrasonic therapeutic transducer connected to said power source and modulator assembly and configured to convert the modulated electrical power to ultrasonic energy directed at a target volume in a region of a body containing adipose and non-adipose tissue, so as to selectively generally lyse the adipose tissue and generally not lyse the non-adipose tissue; an ultrasonic imaging sub-system configured to identify changes in the target volume resulting from the ultrasonic energy; and a lipolysis control computer configured to control said power source and modulator assembly based on the changes identified by said ultrasonic imaging sub-system.
In some embodiments, said ultrasonic imaging sub-system comprises an ultrasonic imaging transducer and an ultrasonic reflection analyzer.
In some embodiments, the changes identified by said ultrasonic imaging sub-system comprise cavitation in the target volume.
In some embodiments, the changes identified by said ultrasonic imaging sub-system comprise lysis of adipose tissue in the target volume.
In some embodiments, said ultrasonic therapeutic transducer comprises a director configured to vary a focus of the ultrasonic energy directed towards the target volume.
In some embodiments, the varying of the focus comprises changing a volume of said target volume.
In some embodiments, the varying of the focus comprises changing a distance of said target volume from said ultrasonic therapeutic transducer.
There is further provided, in accordance with an embodiment, a method for selectively lysing adipose tissue, the method comprising: generating a time-varying electrical signal having a series of relatively high amplitude portions separated in time by a series of relatively low amplitude portions; converting the electrical signal to a corresponding ultrasonic signal; and directing the ultrasonic signal towards a target volume in a region of a body containing adipose and non-adipose tissue, thereby inducing selective cavitation in the adipose tissue while generally not lysing the non-adipose tissue in the target volume.
In some embodiments, the series of relatively high amplitude portions comprises: one or more initial portions having amplitude above a cavitation initiation threshold; and later portions having an amplitude above a cavitation maintenance threshold.
In some embodiments, the series of relatively low amplitude portions comprises portions having amplitude below the cavitation initiation and maintenance thresholds.
In some embodiments, the series of relatively high amplitude portions comprises between 25-500 relatively high amplitude portions.
In some embodiments, the generating of the time-varying electrical signal comprises generating the series of the relatively high amplitude portions and the series of relatively low amplitude portions at a duty cycle of between 1:5 and 1:20.
In some embodiments, the ultrasonic signal has a frequency in the range of 150-1000 KHz.
There is yet further provided, in accordance with an embodiment, an automatically-positionable adipose tissue lysis apparatus, comprising: an ultrasonic transducer secured to a three-dimensional positioning assembly, said ultrasonic transducer being configured to direct ultrasonic energy at a target volume in a region of a body containing adipose and non-adipose tissue, so as to selectively generally lyse the adipose tissue and generally not lyse the non-adipose tissue; a lipolysis control computer having a video camera connected thereto, said video camera being configured to externally image a portion of the body, and said lipolysis control computer being configured to detect indications on the imaged portion of the body; and a positioning control unit configured to control said three-dimensional positioning assembly so as to automatically position said ultrasonic transducer based on the detected indications.
In some embodiments, the apparatus further comprises a lipolysis control computer connected to said positioning control unit and configured to control the directing of the ultrasonic energy from said ultrasonic transducer based on the detected indications.
In some embodiments, the apparatus further comprises an ultrasonic imaging sub-system connected to said lipolysis control computer and configured to identify changes in the target volume resulting from the ultrasonic energy, wherein said lipolysis control computer is further configured to control the directing of the ultrasonic energy from said ultrasonic transducer based on the identified changes.
In some embodiments, the changes identified by said ultrasonic imaging sub-system comprise cavitation in the target volume.
In some embodiments, the changes identified by said ultrasonic imaging sub-system comprise lysis of adipose tissue in the target volume.
In some embodiments, the apparatus further comprises an ultrasonic imaging sub-system connected to said lipolysis control computer and configured to detect thicknesses of tissue layers in the region of the body, wherein said lipolysis control computer is further configured to control the directing of the ultrasonic energy from said ultrasonic transducer based on the detected thicknesses.
In some embodiments, said lipolysis control computer is further configured to control a focus of said ultrasonic transducer, so as to vary a distance of said target volume from said ultrasonic transducer.
The present invention will be understood and appreciated more fully from the following detailed description, taken in conjunction with the drawings in which:
Reference is now made to
A preferred embodiment of ultrasonic energy generator and director useful in the present invention comprises an ultrasonic therapeutic transducer 13 including a curved phased array 14 of piezoelectric elements 15, typically defining a portion of a sphere or of a cylinder, and having conductive coatings 16 on opposite surfaces thereof. The piezoelectric elements 15 may be of any suitable configuration, shape and distribution. An intermediate element 18, formed of a material, such as polyurethane, which has acoustic impedance similar to that of soft mammalian tissue, generally fills the curvature defined by phased array 14 and defines a contact surface 20 for engagement with the body, typically via a suitable coupling gel (not shown). Contact surface 20 may be planar, but need not be.
Suitably modulated AC electrical power is supplied by conductors 22 to conductive coatings 16 to cause the piezoelectric elements 15 to provide a desired focused acoustic energy output.
In accordance with a preferred embodiment of the present invention an imaging ultrasonic transducer subassembly 23 is incorporated within transducer 10 and typically comprises a piezoelectric element 24 having conductive surfaces 26 associated with opposite surfaces thereof. Suitably modulated AC electrical power is supplied by conductors 32 to conductive surfaces 26 in order to cause the piezoelectric element 24 to provide an acoustic energy output. Conductors 32, coupled to surfaces 26, also provide an imaging output from imaging ultrasonic transducer subassembly 23.
It is appreciated that any suitable commercially available ultrasonic transducer may be employed or alternatively, imaging ultrasonic transducer subassembly 23 may be eliminated.
It is further appreciated that various types of ultrasonic transducers 10 may be employed. For example, such transducers may include multiple piezoelectric elements, multilayered piezoelectric elements and piezoelectric elements of various shapes and sizes arranged in a phase array.
In a preferred embodiment of the present invention shown in
In accordance with a preferred embodiment of the present invention, a skin temperature sensor 34, such as an infrared sensor, may be mounted alongside imaging ultrasonic transducer subassembly 23. Further in accordance with a preferred embodiment of the present invention a transducer temperature sensor 36, such as a thermocouple, may also be mounted alongside imaging ultrasonic transducer subassembly 23.
Ultrasonic transducer 10 preferably receives suitably modulated electrical power from a power source and modulator assembly 40, forming part of a control subsystem 42. Control subsystem 42 also typically includes a lipolysis control computer 44, having associated therewith a camera 46, such as a video camera, and a display 48. A preferred embodiment of power source and modulator assembly 40 is illustrated in
In accordance with a preferred embodiment of the present invention, camera 46 is operative for imaging a portion of the body on which lipolysis is to be performed. A picture of the portion of the patient's body viewed by the camera is preferably displayed in real time on display 48.
An operator may designate the outline of a region containing adipose tissue. In accordance with one embodiment of the present invention, designation of this region is effected by an operator marking the skin of a patient with an outline 50, which outline is imaged by camera 46 and displayed by display 48 and is also employed by the lipolysis control computer 44 for controlling the application of ultrasonic energy to locations within the region. A computer calculated representation of the outline may also be displayed on display 48, as designated by reference numeral 52. Alternatively, the operator may make a virtual marking on the skin, such as by using a digitizer (not shown), which also may provide computer calculated outline representation 52 on display 48.
In addition to the outline representation 52, the functionality of the system of the present invention preferably also employs a plurality of markers 54 which are typically located outside the region containing adipose tissue, but may be located inside the region designated by outline 50. Markers 54 are visually sensible markers, which are clearly seen by camera 46, captured by camera 46 and displayed on display 48. Markers 54 may be natural anatomic markers, such as distinct portions of the body or alternatively artificial markers such as colored stickers. These markers are preferably employed to assist the system in dealing with deformation of the region nominally defined by outline 50 due to movement and reorientation of the body. Preferably, the transducer 10 also bears a visible marker 56 which is also captured by camera 46 and displayed on display 48.
Markers 54 and 56 are typically processed by computer 44 and may be displayed on display 48 as respective computed marker representations 58 and 60 on display 48.
Reference is now
Preferably the relationship between the time durations of portions 102 and portions 104 is such as to provide a duty cycle between 1:2 and 1:250, more preferably between 1:5 and 1:30 and most preferably between 1:10 and 1:20.
Preferably, the output of signal generator 100 has a frequency in a range of 50 KHz-1000 KHz, more preferably between 100 KHz-500 KHz and most preferably between 150 KHz-300 KHz.
The output of signal generator 100 is preferably provided to a suitable power amplifier 106, which outputs via impedance matching circuitry 108 to an input of ultrasonic transducer 10 (
Each relatively high amplitude portion 102 preferably corresponds to a cavitation period and has an amplitude at a target volume 12 (
Relatively low amplitude portions 114 have an amplitude which lies below both thresholds 120 and 122.
Preferably the relationship between the time durations of portions 112 and portions 114 is such as to provide a duty cycle between 1:2 and 1:250, more preferably between 1:5 and 1:30 and most preferably between 1:10 and 1:20.
Preferably, the ultrasonic energy output of ultrasonic transducer 10 has a frequency in a range of 50 KHz-1000 KHz, more preferably between 100 KHz-500 KHz and most preferably between 150 KHz-300 KHz.
Preferably, each high amplitude portion 112 is comprised of between 2 and 1000 sequential cycles at an amplitude above the cavitation maintaining threshold 120, more preferably between 25 and 500 sequential cycles at an amplitude above the cavitation maintaining threshold 120 and most preferably between 100 and 300 sequential cycles at an amplitude above the cavitation maintaining threshold 120.
Reference is now made to
It is seen the various target volumes 12 are shown with different shading in order to indicate their treatment status. For example, unshaded target volumes, here designated by reference numerals 204 have already experienced lipolysis. A blackened target volume 12, designated by reference numeral 205 is the target volume next in line for lipolysis. A partially shaded target volume 206 typically represents a target volume which has been insufficiently treated to achieve complete lipolysis, typically due to an insufficient treatment duration.
Other types of target volumes, such as those not to be treated due to insufficient presence of adipose tissue therein or for other reasons, may be designated by suitable colors or other designations, and are here indicated by reference numerals 208 and 210.
Typical performance messages 202 may include “CAVITATION IN PROCESS” and “FAT LYSED IN THIS VOLUME”. Typical status messages 203 may include an indication of the power level, the operating frequency, the number of target volumes 12 within the calculated target region 200 and the number of target volumes 12 which remain to undergo lipolysis.
Display 48 also preferably includes an graphical cross sectional indication 212 derived from an ultrasonic image preferably provided by imaging ultrasonic transducer subassembly 23 (
Turning to
Typical warning messages may include “BAD ACOUSTIC CONTACT”, “TEMPERATURE TOO HIGH”. The “TEMPERATURE TOO HIGH” message typically relates to the skin tissue, although it may alternatively or additionally relate to other tissue inside or outside of the target volume or in transducer 10 (
Reference is now made to
Lipolysis control computer 44 also preferably receives an input from an acoustic contact monitoring unit 302, which in turn preferably receives an input from a transducer electrical properties measurement unit 304. Transducer electrical properties measurement unit 304 preferably monitors the output of power source and modulator assembly 40 (
An output of transducer electrical properties measurement unit 304 is preferably also supplied to a power meter 306, which provides an output to the lipolysis control computer 44 and a feedback output to power source and modulator assembly 40.
Lipolysis control computer 44 also preferably receives inputs from cavitation detection functionality 308, tissue layer identification functionality 310 and lysed adipose tissue identification functionality 312, all of which receive inputs from ultrasonic reflection analysis functionality 314. Ultrasonic reflection analysis functionality 314 receives ultrasonic imaging inputs from an ultrasonic imaging subsystem 316, which operates ultrasonic imaging transducer 23 (
Lipolysis control computer 44 provides outputs to power source and modulator assembly 40, for operating ultrasonic therapeutic transducer 13, and to ultrasonic imaging subsystem 316, for operating ultrasonic imaging transducer 23. A positioning control unit 318 also receives an output from lipolysis control computer 44 for driving X-Y-Z positioning assembly 49 (
Reference is now made to
Camera 46 (
A computerized tracking functionality preferably embodied in lipolysis control computer 44 preferably employs the output of camera 46 for computing outline representation 52, which may be displayed for the operator on display 48. The computerized tracking functionality also preferably computes coordinates of target volumes for lipolysis treatment, as well as adding up the total volume of tissue sought to undergo lipolysis.
Preferably, the operator confirms the locations of markers 54 and 56 on display 48 and the computerized tracking functionality calculates corresponding marker representations 58 and 60.
In accordance with a preferred embodiment of the present invention the computerized tracking functionality employs markers 54 and marker representations 58 for continuously maintaining registration of outline 50 with respect to outline representation 52, and thus of target volumes 12 with respect to the patient's body, notwithstanding movements of the patients body during treatment, such as due to breathing or any other movements, such as the patient leaving and returning to the treatment location.
The computerized tracking functionality selects an initial target volume to be treated and positioning control unit 318 (
Referring additionally to
Based on an output from ultrasonic reflection analysis functionality 314, the thicknesses of the various tissue layers of the patient are determined. Upon receiving an indication of the tissue layer thicknesses, an operator may approve the selected target volume and activates the power source and modulator assembly 40 (
Turning additionally to
Transducer electrical properties measurement unit 304 provides an output to acoustic contact monitoring unit 302, which determines whether sufficient acoustic contact with the patient is present, preferably by analyzing the current and voltage at therapeutic transducer 13.
Transducer electrical properties measurement unit 304 provides an output to power meter 306, which computes the average electrical power received by the therapeutic transducer 13. If the average electrical power received by the therapeutic transducer 13 exceeds a predetermined threshold, operation of the power source and modulator assembly 40 may be automatically terminated.
Skin temperature sensor 34 measures the current temperature of the skin at transducer 10 and supplies it to temperature measurement unit 300, which compares the skin temperature to the threshold temperature. Similarly, transducer temperature sensor 36 measures the current temperature at transducer 10 and supplies it to temperature measurement unit 300, which compares the transducer temperature to the threshold temperature. The outputs of temperature measurement unit 300 are supplied to lipolysis control computer 44.
The ultrasonic imaging subsystem 316 operates ultrasonic imaging transducer 23 and receives an imaging output, which is analyzed by ultrasonic reflection analysis functionality 314. The result of this analysis is employed for cavitation detection and a cavitation detection output is supplied to lipolysis control computer 44.
Should any of the following four conditions occur, the power source and modulator assembly 40 automatically terminates operation of therapeutic transducer 13. Should none of the following conditions occur, the automatic operation of power source and modulator assembly 40 continues:
1. Acoustic contact is insufficient.
2. Skin temperature exceeds threshold temperature level.
3. Transducer 13 temperature exceeds threshold temperature level.
4. Cavitation is not detected.
Returning to
If, however, the transducer 10 did not remain stationary for a sufficient duration, the selected target volume is designated by lipolysis control computer 44 as having been insufficiently treated.
It is appreciated that by using multiple transducers multiplicity of target volumes can be treated at various time patterns such as sequential time patterns or partially overlapping time patterns.
It is also appreciated that the multiplicity of target volumes may also overlap in space or partially overlap in space.
The computational tracking functionality is set forth in the Computer Program Listing Appendix of U.S. Pat. No. 7,347,855, which is incorporated herein by reference in its entirety.
It will be appreciated by persons skilled in the art that the present invention is not limited by what has been particularly shown and described hereinabove. Rather the scope of the present invention includes both combinations and subcombinations of the various features described hereinabove as well as variations and modifications which would occur to persons skilled in the art upon reading the specification and which are not in the prior art.
This application is a continuation of U.S. patent application Ser. No. 12/071,382, filed Feb. 20, 2008, which is a continuation of U.S. patent application Ser. No. 10/021,238, now U.S. Pat. No. 7,347,855, filed Oct. 29, 2001.
Number | Name | Date | Kind |
---|---|---|---|
3637437 | Goldberger | Jan 1972 | A |
3735755 | Eggleton | May 1973 | A |
4043946 | Sanker | Aug 1977 | A |
4049580 | Oden | Sep 1977 | A |
4110257 | O'Hare | Aug 1978 | A |
4116804 | Needes | Sep 1978 | A |
4126934 | Richter | Nov 1978 | A |
4169025 | Needes | Sep 1979 | A |
4450056 | Gray | May 1984 | A |
4605009 | Pourcelot | Aug 1986 | A |
4727903 | Sturgis | Mar 1988 | A |
4826799 | Cheng | May 1989 | A |
4827911 | Broadwin | May 1989 | A |
4853122 | McCray | Aug 1989 | A |
4886491 | Parisi | Dec 1989 | A |
4938216 | Lele | Jul 1990 | A |
4951653 | Fry | Aug 1990 | A |
4986275 | Ishida | Jan 1991 | A |
5005579 | Wurster | Apr 1991 | A |
5079952 | Nakaso | Jan 1992 | A |
5080102 | Dory | Jan 1992 | A |
5111822 | Dory | May 1992 | A |
5143063 | Fellner | Sep 1992 | A |
5143073 | Dory | Sep 1992 | A |
5209221 | Riedlinger | May 1993 | A |
5211164 | Allen | May 1993 | A |
5219401 | Cathignol | Jun 1993 | A |
5301660 | Rattner | Apr 1994 | A |
5413550 | Castel | May 1995 | A |
5419761 | Narayanan | May 1995 | A |
5431621 | Dory | Jul 1995 | A |
5507790 | Weiss | Apr 1996 | A |
5512327 | Chakraborty | Apr 1996 | A |
5526815 | Granz | Jun 1996 | A |
5601526 | Chapelon | Feb 1997 | A |
5618275 | Bock | Apr 1997 | A |
5640371 | Schmidt | Jun 1997 | A |
5643179 | Fujimoto | Jul 1997 | A |
5694936 | Fujimoto | Dec 1997 | A |
5762066 | Law | Jun 1998 | A |
5827204 | Grandia | Oct 1998 | A |
5884631 | Silberg | Mar 1999 | A |
5938608 | Bieger | Aug 1999 | A |
5944663 | Kuth | Aug 1999 | A |
5948011 | Knowlton | Sep 1999 | A |
5993979 | Figueroa | Nov 1999 | A |
6038467 | De Bliek | Mar 2000 | A |
6039048 | Silberg | Mar 2000 | A |
6071239 | Cribbs et al. | Jun 2000 | A |
6086535 | Ishibashi | Jul 2000 | A |
6113558 | Rosenschein | Sep 2000 | A |
6176840 | Nishimura | Jan 2001 | B1 |
6203540 | Weber | Mar 2001 | B1 |
6206873 | Paolini | Mar 2001 | B1 |
6384516 | Fraser | May 2002 | B1 |
6387116 | McKenzie | May 2002 | B1 |
6573213 | Ostgard | Jun 2003 | B1 |
6575922 | Fearnside | Jun 2003 | B1 |
6595934 | Hissong | Jul 2003 | B1 |
6605080 | Altshuler et al. | Aug 2003 | B1 |
6607498 | Eshel | Aug 2003 | B2 |
6645162 | Friedman | Nov 2003 | B2 |
6684097 | Parel | Jan 2004 | B1 |
6747180 | Ostgard | Jun 2004 | B2 |
7258674 | Cribbs | Aug 2007 | B2 |
7331951 | Eshel | Feb 2008 | B2 |
7347855 | Eshel | Mar 2008 | B2 |
20020112541 | Lee | Aug 2002 | A1 |
20020156415 | Redding | Oct 2002 | A1 |
20030040743 | Cosman | Feb 2003 | A1 |
20030083536 | Eshel | May 2003 | A1 |
20040049134 | Tosaya | Mar 2004 | A1 |
20050283097 | Weintraub | Dec 2005 | A1 |
20060173340 | Umemura | Aug 2006 | A1 |
20060241440 | Eshel | Oct 2006 | A1 |
Number | Date | Country |
---|---|---|
1060728 | Dec 2000 | EP |
2303552 | Feb 1997 | GB |
58181399 | Oct 1983 | JP |
08089893 | Apr 1996 | JP |
9-103434 | Apr 1997 | JP |
10277483 | Oct 1998 | JP |
11155894 | Jun 1999 | JP |
11187493 | Jul 1999 | JP |
2001-286484 | Oct 2001 | JP |
9503740 | Feb 1995 | WO |
9853787 | Dec 1998 | WO |
0053263 | Sep 2000 | WO |
0187161 | Nov 2001 | WO |
0224076 | Mar 2002 | WO |
02054018 | Jul 2002 | WO |
Entry |
---|
Ter Haar, Gail R. et al., “Evidence for Acoustic Cavitation In Vivo: Thresholds for Bubble Formation with 0.75-MHz Continuous Wave and Pulsed Beams”, IEEE Transcriptions on Ultrasonics, Ferroelectrics, and Frequency Control 33 (2):162-164 (1986). |
Muir et al., “Prediction of nonlinear acoustic effects at biomedical frequencies and intensities”, Ultrasound in Medicine & Biology 6(4):345-357. (1980). |
Rohrich et al., “Comparative lipoplasty analysis of in vivo-treated adipose tissue”, Plast Reconstr Surg. 105 (6):2152-2158: discussion 2159-2160. (2000). |
Tavakkoli et al., “A piezocomposite shock wave generator with electronic focusing capability: application for producing cavitation-induced lesions in rabbit liver”, Ultrasound Med Biol. 23(1):107-115. (1997). |
Vykhodtseva et al., “Histologic effects of high intensity pulsed ultrasound exposure with subharmonic emission in rabbit brain in vivo”, Ultrasound Med Biol. 21(7):969-979. (1995). |
Number | Date | Country | |
---|---|---|---|
20110087099 A1 | Apr 2011 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12071382 | Feb 2008 | US |
Child | 12971603 | US | |
Parent | 10021238 | Oct 2001 | US |
Child | 12071382 | US |